Company Overview
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.30.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -36.84% |
| 6 Months: | -14.27% |
| 3 Months: | -26.80% |
| 1 Month: | +23.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)47.11 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 61.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EXOZ eXoZymes, Inc. PHARMA | 6.31 | -5.26 | $58.57M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -391.85K | -1.01M | -1.33M | -1.61M | -1.95M | -2.55M | -2.52M | -2.39M |
| Net Income | -241.15K | -178.08K | -520.60K | -1.01M | -1.36M | -1.66M | -1.86M | -2.36M | -2.29M | -2.37M |
| Diluted EPS | - | - | -0.08 | -0.16 | -0.22 | -0.27 | -0.22 | -0.28 | -0.27 | -0.28 |
| R&D Expense | - | - | 27.94K | 277.58K | 237.40K | 723.49K | 575.02K | 802.99K | 1.22M | 1.12M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 70.07K | - | - |
| Operating Income | -1.80M | -5.93M | -9.72M |
| Net Income | -2.04M | -5.86M | -9.16M |
| Diluted EPS | -0.33 | -0.89 | -1.09 |
| R&D Expense | 527.48K | 1.87M | 3.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 3.56M | 13.03M | 5.97M |
| Total Equity | 1.37M | -384.32K | 10.42M | 3.40M |
| Cash & Equivalents | - | 66.53K | 9.72M | 3.04M |
| Total Liabilities | - | 3.94M | 2.61M | 2.57M |
| Current Liabilities | - | 2.42M | 1.33M | 1.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -1.18M | -8.51M | -6.50M |
| Investing Cash Flow | -311.17K | -359.22K | -150.22K |
| Financing Cash Flow | 1.00M | 18.52M | -27.71K |
| Capital Expenditure | -288.71K | -396.45K | -169.92K |
| Free Cash Flow | -1.47M | -8.90M | -6.67M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -2,563.5% | - | - |
| Net Margin % | -2,909.1% | - | - |
| ROE % | 530.4% | -56.2% | -269.6% |
| ROCE % | -157.1% | -50.7% | -220.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 0.59% | 54.98K | $353.83K |
| 2 | Davidson Kahn Capital Management, LLC | 0.27% | 25.00K | $160.87K |
| 3 | Geode Capital Management, LLC | 0.25% | 23.41K | $150.62K |
| 4 | Blackrock Inc. | 0.10% | 9.61K | $61.84K |
| 5 | Vanguard Fiduciary Trust Co | 0.10% | 9.43K | $60.66K |
| 6 | Morgan Stanley | 0.01% | 1.25K | $8.04K |
| 7 | Tower Research Capital LLC (TRC) | - | 349 | $2.25K |
| 8 | UBS Group AG | - | 203 | $1.31K |
| 9 | Barclays Plc | - | 75 | $482 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EXOZ
A 3,000-employee manufacturer will help eXoZymes move a product toward larger-scale production. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOeEhQVEFvdjNkUmdKVGJ4YTFzY21BSWdSYnhmRHpMMFlyaHktZEp4TGplZWNfdlFTQ21vM2NnUlBYbDE2bWdmYWNxZnROLUd1b24xTGtqVHZIaTBad09PbTExbHNjYldqa2tPSzJCTFo5TE94UDZIY3lQb244VGk4WXdIdWVKX3RnWk1jU2…
How EXOZ Company (EXOZ) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQNXhUaUVsS0RLN2Z6T2NsRmNIaHlDTlZkQ2RuQkFSMGphU2FDYXViM3lQYXlwQkFnUGtTQ0trV3pXWThHWVZVNTNmNGtQT0otYXZXOGUzbU1nWTJhcGh6Y1RjX3NVNkJHNldBNjBNaGlUb0F0NzBid1Z3Z1o5MzV2N0gzQllfZkdjSXhob1…
exozymes partners with Curia for NCT manufacturing scale-up By Investing.com - Investing.com Canada
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSDRJQmY2dVdaMHdvQ0RRSnpvX1B2V0RRMXpfS0wzNGptX3BDalFMZEtCdjdzQ3BXT1BkZ1NvOHlUT2lCOGhrZ19zSkFuU0JGQ1FOMFI4ejZxZzZwLXBnRk5SWTF1RS1aeGFzc2U2MGkzaFJlTEZoTjRvcXViNUxyYjFwMlJtU0V0TXZIcW…
Exozymes (EXOZ) CEO adds stock with August buys and grant - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYVF0V1dZajRUUWdtVjhZX3FBSHBHSXNnYmo5dm8tbzZEWFl6ZndnMWRIWGQ5STBscWNlZmNick9jQUI4R1FnX3NCOHAwSjFtRnppZGhlUXZ2UmtOZmQ2RUNJR05kUUpmNWtYekR4dDh0eXJTc09ldWVMc2hueDFiM3FqNmVRQzc5Wmc2Wn…
Will eXoZymes (NASDAQ:EXOZ) Spend Its Cash Wisely? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQbzJHaTZWZTJjQ2FFZ3dHcWVWUHlnZXhZMGNaQ0JtS0hnNFVwRHFkbjMwUW4wNy1lTWdSbEtTYmEyVjJ0T2dObjBwY01SU0ZjNVJhYTNmVGRtdjUyQmtfMGd0VzR1TUw5eFRvSU9GOTF5X1F6cHkzYl93VkZqODh3ZjhoQVRPTkI4TVhhZG…
Will eXoZymes (NASDAQ:EXOZ) Spend Its Cash Wisely? - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTFAtSFpsb1I0bm1DT3pmVGRrdWVYd2g4ekkyWXZKeEEzZVgxRS1sWm43RlQxRS1Md1ltbVhGMkFCdmIySlFqRmpBTGFXX2VzdWxtQjJSNW1nWGk?oc=5" target="_blank">Will eXoZymes (NASDAQ:EXOZ) Spend Its Cash Wisel…
EXOZ — Frequently Asked Questions
What is the current share price of eXoZymes, Inc. (EXOZ)?
As of 2026-09-19 21:16 PDT, eXoZymes, Inc. (EXOZ) trades at $6.31 on NasdaqCM. Its 52-week range is $4.40 to $16.50.
What is the market capitalisation of EXOZ?
eXoZymes, Inc. (EXOZ) has a market capitalisation of $58.57M on NasdaqCM.
What is the P/E ratio of EXOZ?
EXOZ trades at a trailing price-to-earnings (P/E) ratio of -5.26. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 15.66.
Is EXOZ a good stock to buy?
This page provides a data-driven analysis of eXoZymes, Inc. (EXOZ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.